NASDAQ:ONVO - Organovo Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.03 -0.09 (-8.04 %)
(As of 01/21/2019 04:00 PM ET)
Previous Close$1.12
Today's Range$1.03 - $1.14
52-Week Range$0.90 - $2.09
Volume875,872 shs
Average Volume607,129 shs
Market Capitalization$119.37 million
P/E Ratio-3.22
Dividend YieldN/A
Beta1.94
Organovo Holdings, Inc., a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat a range of rare, life-threatening diseases. In addition, the company offers preclinical in vitro disease modeling platforms, including a range of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis conditions. Further, it involved in various programs to develop its NovoTissues transplantable tissues to address various serious unmet medical needs in adult and pediatric populations primarily focusing on liver disease. The company was founded in 2007 and is headquartered in San Diego, California.

Receive ONVO News and Ratings via Email

Sign-up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONVO
CUSIPN/A
Phone858-224-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.60 million
Book Value$0.40 per share

Profitability

Net Income$-34,800,000.00
Net Margins-732.47%

Miscellaneous

Employees75
Market Cap$119.37 million
OptionableOptionable

Organovo (NASDAQ:ONVO) Frequently Asked Questions

What is Organovo's stock symbol?

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

How were Organovo's earnings last quarter?

Organovo Holdings Inc (NASDAQ:ONVO) posted its quarterly earnings results on Thursday, November, 8th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.03. The medical research company had revenue of $0.94 million for the quarter, compared to the consensus estimate of $0.90 million. Organovo had a negative return on equity of 65.73% and a negative net margin of 732.47%. View Organovo's Earnings History.

When is Organovo's next earnings date?

Organovo is scheduled to release their next quarterly earnings announcement on Thursday, February 7th 2019. View Earnings Estimates for Organovo.

What price target have analysts set for ONVO?

2 brokerages have issued 12 month price targets for Organovo's shares. Their forecasts range from $1.75 to $2.50. On average, they anticipate Organovo's share price to reach $2.1250 in the next year. This suggests a possible upside of 106.3% from the stock's current price. View Analyst Price Targets for Organovo.

What is the consensus analysts' recommendation for Organovo?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organovo in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Organovo.

Has Organovo been receiving favorable news coverage?

Media coverage about ONVO stock has trended very positive on Monday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Organovo earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are some of Organovo's key competitors?

Who are Organovo's key executives?

Organovo's management team includes the folowing people:
  • Mr. Taylor J. Crouch, CEO, Pres & Director (Age 59)
  • Mr. Craig Kussman, Chief Financial Officer (Age 60)
  • Ms. Jennifer Kinsbruner Bush, Sr. VP, Compliance Officer, Gen. Counsel & Corp. Sec. (Age 44)
  • Mr. Paul Gallant, Gen. Mang. (Age 54)
  • Mr. Steve E. Kunszabo, VP of Investor Relations & Corp. Communications

How do I buy shares of Organovo?

Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Organovo's stock price today?

One share of ONVO stock can currently be purchased for approximately $1.03.

How big of a company is Organovo?

Organovo has a market capitalization of $119.37 million and generates $4.60 million in revenue each year. The medical research company earns $-34,800,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Organovo employs 75 workers across the globe.

What is Organovo's official website?

The official website for Organovo is http://www.organovo.com.

How can I contact Organovo?

Organovo's mailing address is 6275 NANCY RIDGE DRIVE SUITE 110, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]


MarketBeat Community Rating for Organovo (NASDAQ ONVO)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  131 (Vote Underperform)
Total Votes:  243
MarketBeat's community ratings are surveys of what our community members think about Organovo and other stocks. Vote "Outperform" if you believe ONVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel